Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate

Urology

Volumn 53, Issue 2, 1999, Pages 423-424

  Curran, Michael J ^a   Bihrle III, William ^a  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGED; ANDROGEN THERAPY; ARTICLE; CASE REPORT; FINGER; HUMAN; HUMAN TISSUE; HYPOGONADISM; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; OCCULT CANCER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; RECTUM;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 0032943937     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00348-3     Document Type: Article

References (6)

1. Cunningham G.R., Cordero E., Thornby J.I. Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels. JAMA. 261:1989;2525-2530.
2. McClure R.D., Oses R., Ernest M.L. Hypogonadal impotence treated by transdermal testosterone. Urology. 37:1991;224-228.
3. Loughlin K.R., Richie J.P. Prostate cancer after exogenous testosterone treatment for impotence. J Urol. 157:1997;1845.
4. Morales A., Johnston B., Heaton J.W., et al. Oral androgens in the treatment of hypogonadal impotent men. J Urol. 152:1994;1115-1118.
5. Morgenthaler A., Bruning C.O. III, DeWolf W.C. Incidence of occult prostate cancer in men with low total or free serum testosterone. JAMA. 276:1996;1904-1906.
6. Jackson J.A., Waxman J., Spiekerman A.M. Prostatic complications of testosterone replacement therapy. Arch Intern Med. 149:1989;2365-2366.